
Vasomune Therapeutics to Showcase Research at Leading Pulmonary Conference
Vasomune Therapeutics to Present Late-Breaking Research on AV-001 at the 2025 American Thoracic Society International Conference Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to address diseases driven by vascular dysfunction, today announced its participation in the 2025…












